drugset / Trial / NCT03550352
Cannabinoids in PLWHIV on Effective ART
Phase 2
Terminated
10 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
CIHR Canadian HIV Trials Network · collabCentre de Recherche du Centre Hospitalier de l'Université de Montréal · collabTilray · collabUniversité du Québec a Montréal · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this pilot study is to assess feasibility and to examine whether oral cannabinoids (capsules containing either Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) combined or CBD alone) are safe and well-tolerated in people living with HIV. Other aims are to determine whether oral cannabinoids may reduce HIV-associated inflammation. An exploratory objective is to determine whether oral cannabinoids may influence HIV persistence as well as the gastrointestinal microbiome.
Timeline
- Start
- 2021-08-20
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 15 mg | Oral |
| Subject | Cannabidiol | Other / unclassified | 800 mg | Oral |
| Subject | Dronabinol | Other / unclassified | 15 mg | Oral |